{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:13Z","timestamp":1792521433084,"version":"4.5.0"},"reference-count":38,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:p>OBJECTIVE. This study evaluated the safety, tolerability, and immunogenicity of live attenuated influenza vaccine administered concurrently with measles-mumps-rubella vaccine and varicella vaccine to healthy children 12 to 15 months of age.<\/jats:p>\n                  <jats:p>METHODS. Children were assigned randomly to receive (1) measles-mumps-rubella vaccine, varicella vaccine, and intranasal placebo on day 0, followed by 1 dose of live attenuated influenza vaccine on days 42 and 72; (2) measles-mumps-rubella, varicella, and live attenuated influenza vaccines on day 0, followed by a second dose of live attenuated influenza vaccine on day 42 and intranasally administered placebo on day 72; or (3) 1 dose of live attenuated influenza vaccine on days 0 and 42, followed by measles-mumps-rubella and varicella vaccines on day 72. Serum samples were collected before vaccination on days 0, 42, and 72. Reactogenicity events and adverse events were collected through day 41 after concurrent vaccinations and through day 10 after administration of live attenuated influenza vaccine or placebo alone.<\/jats:p>\n                  <jats:p>RESULTS. Among 1245 (99.5%) evaluable children, seroresponse rates and geometric mean titers for measles-mumps-rubella vaccine and varicella vaccine were similar with concurrent administration of live attenuated influenza vaccine or placebo (seroresponse rates of \u226596% for measles-mumps-rubella vaccine and \u226582% for varicella vaccine in both groups). Hemagglutinin-inhibiting antibody geometric mean titers and seroconversion rates to influenza strains in live attenuated influenza virus vaccine were similar after the vaccine was administered alone (seroconversion rates of 98%, 92%, and 44% for H3, B, and H1 strains, respectively) or with measles-mumps-rubella and varicella vaccines (seroconversion rates of 98%, 96%, and 43%). The incidences of reactogenicity events and adverse events were similar among treatment groups.<\/jats:p>\n                  <jats:p>CONCLUSIONS. Concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella vaccine and varicella vaccine provided equivalent immunogenicity, compared with separate administration, and was well tolerated.<\/jats:p>","DOI":"10.1542\/peds.2007-1064","type":"journal-article","created":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T09:48:09Z","timestamp":1204278489000},"page":"508-516","source":"Crossref","is-referenced-by-count":39,"title":["Safety and Immunogenicity of Concurrent Administration of Live Attenuated Influenza Vaccine With Measles-Mumps-Rubella and Varicella Vaccines to Infants 12 to 15 Months of Age"],"prefix":"10.1542","volume":"121","author":[{"given":"Terry","family":"Nolan","sequence":"first","affiliation":[{"name":"School of Population Health, University of Melbourne and Murdoch Children's Research Institute, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan L.","family":"Block","sequence":"additional","affiliation":[{"name":"Kentucky Pediatric Research, Bardstown, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo","family":"Hilty","sequence":"additional","affiliation":[{"name":"Pediatric Clinical Trials International, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.","family":"Keyserling","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Epidemiology, and Immunology, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Marchant","sequence":"additional","affiliation":[{"name":"School of Medicine, Boston University Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[{"name":"Discipline of Paediatrics, University of Adelaide and Children, Youth, and Women's Health Service, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital for Children, Subiaco, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Yogev","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Children's Memorial Hospital, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Cordova","sequence":"additional","affiliation":[{"name":"Departments of Clinical Development and Biostatistics, MedImmune, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iksung","family":"Cho","sequence":"additional","affiliation":[{"name":"Departments of Clinical Development and Biostatistics, MedImmune, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Mendelman","sequence":"additional","affiliation":[{"name":"Departments of Clinical Development and Biostatistics, MedImmune, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the LAIV Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,3,1]]},"reference":[{"key":"2021120905494105400_R1","unstructured":"Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0\u201318 years: United States, 2007. MMWR Morb Mortal Wkly Rep.2007;55(51\u201352):Q1\u2013Q4"},{"key":"2021120905494105400_R2","unstructured":"Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep.2002;51(RR-2):1\u201335"},{"key":"2021120905494105400_R3","doi-asserted-by":"crossref","unstructured":"Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med.1998;338(20):1405\u20131412","DOI":"10.1056\/NEJM199805143382002"},{"key":"2021120905494105400_R4","doi-asserted-by":"crossref","unstructured":"Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A\/Sydney) not contained in the vaccine. J Pediatr.2000;136(2):168\u2013175","DOI":"10.1016\/S0022-3476(00)70097-7"},{"key":"2021120905494105400_R5","doi-asserted-by":"crossref","unstructured":"Piedra PA, Yan L, Kotloff K, et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics.2002;110(4):662\u2013672","DOI":"10.1542\/peds.110.4.662"},{"key":"2021120905494105400_R6","doi-asserted-by":"crossref","unstructured":"Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J.2006;25(7):590\u2013595","DOI":"10.1097\/01.inf.0000220229.51531.47"},{"key":"2021120905494105400_R7","doi-asserted-by":"crossref","unstructured":"Ashkenazi S, Vertruyen A, Ari\u0301stegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J.2006;25(10):870\u2013879","DOI":"10.1097\/01.inf.0000237829.66310.85"},{"key":"2021120905494105400_R8","doi-asserted-by":"crossref","unstructured":"Belshe RB, Edwards KM, Vesikari T, et al. Comparative safety and efficacy of live attenuated and inactivated influenza vaccines in infants and young children. N Engl J Med.2007;356(7):685\u2013696","DOI":"10.1056\/NEJMoa065368"},{"key":"2021120905494105400_R9","doi-asserted-by":"crossref","unstructured":"Vesikari T, Fleming DM, Aristegui JF, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics.2006;118(6):2298\u20132312","DOI":"10.1542\/peds.2006-0725"},{"key":"2021120905494105400_R10","unstructured":"Merck. MMR II (Measles, Mumps, and Rubella Virus Vaccine Live): Full Prescribing Information. Whitehouse Station, NJ: Merck;2003"},{"key":"2021120905494105400_R11","unstructured":"Merck. Varivax (Varicella Virus Vaccine Live [Oka\/Merck]): Full Prescribing Information. Whitehouse Station, NJ: Merck;2005"},{"key":"2021120905494105400_R12","unstructured":"Centers for Disease Control and Prevention. The 1995\u201396 WHO Influenza Reagent Kit for the Identification of Influenza Isolates. Atlanta, GA: Centers for Disease Control and Prevention;1995"},{"key":"2021120905494105400_R13","unstructured":"Brammer L, Fukuda K, Arden N. Influenza surveillance: United States, 1992\u201393 and 1993\u201394. MMWR Survill Summ.1997;46(SS-1):1\u201312"},{"key":"2021120905494105400_R14","doi-asserted-by":"crossref","unstructured":"Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med.1985;4(2):213\u2013226","DOI":"10.1002\/sim.4780040211"},{"key":"2021120905494105400_R15","doi-asserted-by":"crossref","unstructured":"Chan IS, Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics.1999;55(4):1202\u20131209","DOI":"10.1111\/j.0006-341X.1999.01202.x"},{"key":"2021120905494105400_R16","doi-asserted-by":"crossref","unstructured":"Loughlin J, Poulios N, Napalkov P, Wegmuller Y, Monto AS. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics.2003;21(4):273\u2013283","DOI":"10.2165\/00019053-200321040-00005"},{"key":"2021120905494105400_R17","doi-asserted-by":"crossref","unstructured":"O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics.2004;113(3):585\u2013593","DOI":"10.1542\/peds.113.3.585"},{"key":"2021120905494105400_R18","doi-asserted-by":"crossref","unstructured":"Grijalva CG, Craig AS, Dupont WD, et al. Estimating influenza hospitalizations among children. Emerg Infect Dis.2006;12(1):103\u2013109","DOI":"10.3201\/eid1201.050308"},{"key":"2021120905494105400_R19","doi-asserted-by":"crossref","unstructured":"Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003\u20132004. N Engl J Med.2005;353(24):2559\u20132567","DOI":"10.1056\/NEJMoa051721"},{"key":"2021120905494105400_R20","doi-asserted-by":"crossref","unstructured":"Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA.2003;289(2):179\u2013186","DOI":"10.1001\/jama.289.2.179"},{"key":"2021120905494105400_R21","unstructured":"Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule: United States, 2006. MMWR.2006;54(52):Q1\u2013Q4"},{"key":"2021120905494105400_R22","unstructured":"Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.2006;55(RR-15):1\u201348"},{"key":"2021120905494105400_R23","doi-asserted-by":"crossref","unstructured":"Petralli JK, Merigan TC, Wilbur JR. Action of endogenous interferon against vaccinia infection in children. Lancet.1965;2:401\u2013405","DOI":"10.1016\/S0140-6736(65)90755-5"},{"key":"2021120905494105400_R24","doi-asserted-by":"crossref","unstructured":"Petralli JK, Merigan TC, Wilbur JR. Circulating interferon after measles vaccination. N Engl J Med.1965;273(4):198\u2013201","DOI":"10.1056\/NEJM196507222730405"},{"key":"2021120905494105400_R25","unstructured":"Centers for Disease Control and Prevention. Simultaneous administration of varicella vaccine and other recommended childhood vaccines: United States, 1995\u20131999. MMWR Morb Mortal Wkly Rep.2001;50(47):1058\u20131061"},{"key":"2021120905494105400_R26","doi-asserted-by":"crossref","unstructured":"Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics.2003;112(2). Available at: www.pediatrics.org\/cgi\/content\/full\/112\/2\/e98","DOI":"10.1542\/peds.112.2.e98"},{"key":"2021120905494105400_R27","doi-asserted-by":"crossref","unstructured":"Giammanco G, De Grandi V, Lupo L, et al. Interference of oral poliovirus vaccine on RIT 4237 oral rotavirus vaccine. Eur J Epidemiol.1988;4(1):121\u2013123","DOI":"10.1007\/BF00152704"},{"key":"2021120905494105400_R28","doi-asserted-by":"crossref","unstructured":"Vodopija I, Baklaic Z, Vlatkovic R, et al. Combined vaccination with live oral polio vaccine and the bovine rotavirus RIT 4237 strain. Vaccine.1986;4(4):233\u2013236","DOI":"10.1016\/0264-410X(86)90135-0"},{"key":"2021120905494105400_R29","doi-asserted-by":"crossref","unstructured":"Zangwill KM, Droge J, Mendelman P, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J.2001;20(8):740\u2013746","DOI":"10.1097\/00006454-200108000-00005"},{"key":"2021120905494105400_R30","doi-asserted-by":"crossref","unstructured":"Nolan T, Lee MS, Cordova JM, et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine.2003;21(11\u201312):1224\u20131231","DOI":"10.1016\/S0264-410X(02)00484-X"},{"key":"2021120905494105400_R31","doi-asserted-by":"crossref","unstructured":"Ambrose CS, Walker RE, Connor EM. Live attenuated influenza vaccine in children. Semin Pediatr Infect Dis.2006;17(4):206\u2013212","DOI":"10.1053\/j.spid.2006.08.007"},{"key":"2021120905494105400_R32","doi-asserted-by":"crossref","unstructured":"Shinefield HR, Black SB, Staehle BO, et al. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. Pediatr Infect Dis J.1998;17(11):980\u2013985","DOI":"10.1097\/00006454-199811000-00003"},{"key":"2021120905494105400_R33","doi-asserted-by":"crossref","unstructured":"White CJ, Stinson D, Staehle B, et al. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children: Measles, Mumps, Rubella, Varicella Vaccine Study Group. Clin Infect Dis.1997;24(5):925\u2013931","DOI":"10.1093\/clinids\/24.5.925"},{"key":"2021120905494105400_R34","doi-asserted-by":"crossref","unstructured":"Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol.1989;146:107\u2013116","DOI":"10.1007\/978-3-642-74529-4_12"},{"key":"2021120905494105400_R35","unstructured":"Kemble G, August M, Dawson D, et al. FluMist elicits crossreactive antibodies to Fujian-like A\/H3N2 strains in ferrets (Abstract 1930). Presented at the Pediatric Academic Societies\u2019 2004 Annual Meeting; May 1\u20134,2004; San Francisco, CA"},{"key":"2021120905494105400_R36","doi-asserted-by":"crossref","unstructured":"Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA.1999;282(2):137\u2013144","DOI":"10.1001\/jama.282.2.137"},{"key":"2021120905494105400_R37","doi-asserted-by":"crossref","unstructured":"Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5\u201349 years. Clin Infect Dis.2004;39(7):920\u2013927","DOI":"10.1086\/423001"},{"key":"2021120905494105400_R38","doi-asserted-by":"crossref","unstructured":"Belshe RB, Gruber WC. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children. Philos Trans R Soc Lond B Biol Sci.2001;356(1416):1947\u20131951","DOI":"10.1098\/rstb.2001.0982"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/508\/1124276\/zpe00308000508.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/508\/1124276\/zpe00308000508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T18:40:28Z","timestamp":1639075228000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/3\/508\/72841\/Safety-and-Immunogenicity-of-Concurrent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,3,1]]},"published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-1064","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,1]]}}}